CR20110544A - Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7 - Google Patents

Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7

Info

Publication number
CR20110544A
CR20110544A CR20110544A CR20110544A CR20110544A CR 20110544 A CR20110544 A CR 20110544A CR 20110544 A CR20110544 A CR 20110544A CR 20110544 A CR20110544 A CR 20110544A CR 20110544 A CR20110544 A CR 20110544A
Authority
CR
Costa Rica
Prior art keywords
heterodymer
alfa
beta
antagonist antibody
specific antagonist
Prior art date
Application number
CR20110544A
Other languages
English (en)
Inventor
Hailing Hsu
Ian Foltz
Taruna Arora
Frederick W Jacobsen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20110544A publication Critical patent/CR20110544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen las proteínas de unión al antígeno específicas para el heterodímero de alfa4beta7, los ácidos nucleicos que las codifican y los métodos de fabricarlas y usarlas.
CR20110544A 2009-03-20 2011-10-18 Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7 CR20110544A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22

Publications (1)

Publication Number Publication Date
CR20110544A true CR20110544A (es) 2011-12-07

Family

ID=42224952

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110544A CR20110544A (es) 2009-03-20 2011-10-18 Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7

Country Status (27)

Country Link
US (6) US8444981B2 (es)
EP (1) EP2408816B1 (es)
JP (3) JP5498566B2 (es)
KR (2) KR101391472B1 (es)
CN (2) CN103382222B (es)
AR (1) AR075882A1 (es)
AU (1) AU2010226814B2 (es)
CA (2) CA2851737C (es)
CL (3) CL2011002306A1 (es)
CO (1) CO6501170A2 (es)
CR (1) CR20110544A (es)
EA (1) EA034783B1 (es)
ES (1) ES2751946T3 (es)
HK (1) HK1168116A1 (es)
IL (4) IL214868A (es)
JO (1) JO3615B1 (es)
MA (1) MA33213B1 (es)
MX (4) MX2011009897A (es)
MY (2) MY184957A (es)
NZ (1) NZ595464A (es)
PE (2) PE20120497A1 (es)
SG (3) SG10201400798VA (es)
TN (1) TN2011000433A1 (es)
TW (2) TWI466681B (es)
UY (1) UY32501A (es)
WO (1) WO2010107752A2 (es)
ZA (1) ZA201107279B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107998388B (zh) 2011-05-02 2023-07-14 千禧制药公司 抗α4β7抗体的制剂
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9914779B2 (en) 2011-11-23 2018-03-13 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
CN106062193B (zh) * 2014-02-28 2020-08-25 安斯泰来制药株式会社 与人tlr2及人tlr4结合的双特异性抗体
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
EA201790437A1 (ru) 2014-08-22 2017-08-31 Сорренто Терапьютикс, Инк. Антигенсвязывающие белки, связывающиеся с cxcr3
KR102642382B1 (ko) 2014-10-06 2024-02-29 케모센트릭스, 인크. C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
SG11201800864XA (en) * 2015-08-11 2018-03-28 Univ Osaka Antibody
CN116327920A (zh) * 2016-03-14 2023-06-27 千禧制药公司 预防移植物抗宿主疾病的方法
WO2017160700A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
WO2017164678A2 (ko) * 2016-03-23 2017-09-28 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
JP7202893B2 (ja) 2016-06-12 2023-01-12 武田薬品工業株式会社 炎症性腸疾患を治療する方法
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
WO2018200818A2 (en) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
US11168128B2 (en) 2020-02-26 2021-11-09 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022232943A1 (en) * 2021-03-12 2023-09-28 Icahn School Of Medicine At Mount Sinai Neutralizing monoclonal antibodies to bk virus
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2270425T3 (es) 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002076406A2 (en) * 2001-03-27 2002-10-03 Gershwin M Eric Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
WO2002078779A1 (fr) * 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
RU2339647C2 (ru) * 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Also Published As

Publication number Publication date
TW201036626A (en) 2010-10-16
US8871490B2 (en) 2014-10-28
SG10201801337WA (en) 2018-03-28
AU2010226814B2 (en) 2013-05-16
TW201418281A (zh) 2014-05-16
TWI477511B (zh) 2015-03-21
JO3615B1 (ar) 2020-08-27
IL214868A (en) 2015-08-31
UY32501A (es) 2010-04-30
MA33213B1 (fr) 2012-04-02
AR075882A1 (es) 2011-05-04
US8444981B2 (en) 2013-05-21
JP2014140372A (ja) 2014-08-07
KR101391472B1 (ko) 2014-05-07
CL2014000401A1 (es) 2014-08-29
CO6501170A2 (es) 2012-08-15
IL239965A0 (en) 2015-08-31
EP2408816A2 (en) 2012-01-25
CA2851737C (en) 2019-01-08
WO2010107752A3 (en) 2011-01-20
IL232009A (en) 2015-11-30
CA2851737A1 (en) 2010-09-23
US20120183561A1 (en) 2012-07-19
CN102388068A (zh) 2012-03-21
JP5498566B2 (ja) 2014-05-21
IL232008A0 (en) 2014-05-28
MY162752A (en) 2017-07-14
US8454962B2 (en) 2013-06-04
ES2751946T3 (es) 2020-04-02
MX357213B (es) 2018-06-29
NZ595464A (en) 2013-08-30
JP5775615B2 (ja) 2015-09-09
MX357211B (es) 2018-06-29
WO2010107752A2 (en) 2010-09-23
MX2014013424A (es) 2015-07-29
IL214868A0 (en) 2011-11-30
HK1168116A1 (en) 2012-12-21
EP2408816B1 (en) 2019-09-04
IL232008A (en) 2015-11-30
SG10201400798VA (en) 2014-07-30
US9499620B2 (en) 2016-11-22
SG174344A1 (en) 2011-11-28
CA2754113C (en) 2014-08-05
CL2014000400A1 (es) 2014-08-29
CL2011002306A1 (es) 2012-01-13
EA201171148A1 (ru) 2012-04-30
AU2010226814A1 (en) 2011-09-29
JP2015214563A (ja) 2015-12-03
KR20110128948A (ko) 2011-11-30
PE20160553A1 (es) 2016-05-18
US20170275365A1 (en) 2017-09-28
MY184957A (en) 2021-04-30
US20130302354A1 (en) 2013-11-14
US20100254975A1 (en) 2010-10-07
US20120177662A1 (en) 2012-07-12
IL232009A0 (en) 2014-05-28
CN103382222A (zh) 2013-11-06
TN2011000433A1 (en) 2013-03-27
MX338969B (es) 2016-05-06
IL239965A (en) 2016-10-31
TWI466681B (zh) 2015-01-01
CN103382222B (zh) 2016-12-28
KR20130067314A (ko) 2013-06-21
CA2754113A1 (en) 2010-09-23
CN102388068B (zh) 2015-05-20
US8454961B2 (en) 2013-06-04
EA034783B1 (ru) 2020-03-20
KR101346530B1 (ko) 2013-12-31
JP5980384B2 (ja) 2016-08-31
ZA201107279B (en) 2012-12-27
JP2012520679A (ja) 2012-09-10
US20150086563A1 (en) 2015-03-26
MX2011009897A (es) 2011-12-08
PE20120497A1 (es) 2012-05-14

Similar Documents

Publication Publication Date Title
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CR20120371A (es) Antagonistas de pcsk9
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
DK2794905T3 (da) Modificerede polypeptider til bispecifikke antistofgrundstrukturer
UY34206A (es) Anticuerpo monoclonal de interleucina-31
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
CR20140169A (es) Proteinas de union al antigeno cd27l
AR088920A1 (es) Purificacion de anticuerpos anti-c-met